Recent Posts

Roche’s GA101 (obinutuzumab): Engineering an antibody to beat Rituxan

The following is a guest post from Sally Church (known to many in the...

Biotech, Pharma, & VCs Offer Rare Disease Patient Groups Some Advice

Today’s issue examines the surge of interest in rare disease drugs, which...

New Targets in Advanced Prostate Cancer

The following is a guest post from Sally Church (known to many in the...

New developments in Advanced Pancreatic Cancer from ASCO GI 2013 – Part 2

The following is a guest post from Sally Church (known to many in the...

New Developments in Advanced Pancreatic Cancer from ASCO GI 2013 – Part 1

The following is a guest post from Sally Church (known to many in the...

#FoodChem Carnival: A bit o’ science on your Thanksgiving tippling

In my family, the first thing that happens when you walk in the door to my...

#ChemCoach Carnival: From Big Pharma to Non-Profit

We’re almost at the end of National Chemistry week, folks, and the...

Cantley Talks Pfizer CTI Collaboration

As drug companies forge closer ties with academic researchers, the value of...

After Nutley Closure, Roche Picks NYC For East Coast R&D Site

Just months after announcing it would close its storied Nutley, N.J.,...